TL;DR After the dual regenerative medicine laws take effect on January 1, 2026, Taiwan is gradually forming a three-layer institutional design, each layer connecting to the next: the parent dual regenerative medicine laws, the “conditional approval” under Article 9 of the Regenerative Medicine Products Act (also called conditional approval in this article), and the “Taiwan Regenerative Medicine Advanced Therapy Pilot” (T-RMAT) announced by the TFDA and CDE in March 2026. Set against international frameworks, this design belongs to the same regenerative medicine accelerated-pathway policy trend as the U.S. RMAT, the EU PRIME, and Japan’s Sakigake. The point is not “relaxing review.” It is this: for qualifying products, the competent authority can, when risk-benefit is already preliminarily supported, use post-market verification, risk management, and continuous monitoring to trade for the possibility that patients access treatment options earlier. Taiwan’s regulatory framework is largely in place. What deserves closer watching next is whether industry actually submits applications along this pathway and accumulates verifiable market cases.

▶ Listen to the summary
AI-synthesized voice; a clone of the author's own voice

Recently we have been evaluating whether a cell therapy can land in Taiwan. The therapy has entered mid-to-late-stage clinical evaluation, and we are making a preliminary assessment of its clinical value, regulatory pathway, and commercialization model. My first instinct was that this path would still depend heavily on a complete Phase III, additional local trials, and a long wait for market entry. But once I broke the system apart, I found that over the past few years Taiwan has in fact gradually laid out a pathway quite different from what tradition imagines.

Behind this therapy is a group of patients who have already waited many years. Many regenerative medicine therapies show meaningful efficacy as early as the U.S. Phase II stage, yet patients in Taiwan typically have to wait another 5 to 10 years. By the time the U.S. Phase III is complete, the product reaches market, it is introduced to Taiwan, and it clears health insurance coverage, some people have run out of time. For diseases that progress quickly, every step that can be shortened is, in a real sense, an option.

In June 2024, the Legislative Yuan passed the Regenerative Medicine Act and the Regenerative Medicine Products Act on third reading; they were promulgated by the President and take effect on January 1, 2026. At the same time, the TFDA and the CDE introduced the Taiwan Regenerative Medicine Advanced Therapy Pilot (T-RMAT), announced and launched in March 2026 as a complement to strengthen early regulatory communication, review planning, and pre-submission guidance. With these systems layered together, therapies that “already have Phase II evidence and address life-threatening or severely disabling diseases” now face a more discussable possibility of accelerated entry in Taiwan than before.

This pathway carries at least two common misconceptions. First, many people, on hearing that “a product may apply for conditional approval after completing Phase II,” instinctively ask whether this means review standards have been relaxed. Second, many multinational pharmaceutical companies, when evaluating Asian markets, may still view Taiwan as a market that traditionally takes up U.S. and European data late, and have not yet folded the new system’s conditional approval and guidance pilot into the same strategic calculus. In fact, both instincts deserve reexamination.

Why can a product apply for market after completing Phase II? How the three layers stack

Return to the Regenerative Medicine Products Act itself, and the conditional approval designed in Article 9 is one of this pathway’s cores. Under the provision, an applicant must simultaneously satisfy conditions regarding the specific disease attributes, the clinical trial stage, and the risk-benefit data. Not every product that has completed Phase II can apply directly.

First, the indication must be a “life-threatening disease” or a “severely disabling disease.” “Life-threatening” means the disease has progressed to a stage where it could reasonably cause death within months, or where premature death could occur if treatment is not initiated early; the key is the imminence of mortality risk. “Severely disabling” means the disease has already severely impaired bodily function, affected daily life, or left the patient unable to live independently, and could worsen further if untreated. Transient sequelae or complications that resolve on their own are not included.

Second, the applicant’s product must have completed Phase II human trials. In other words, the product is no longer at the proof-of-concept stage; it has already accumulated safety and preliminary efficacy data at a certain scale in trial subjects.

Third, the applicant must submit data sufficient to support a risk-benefit assessment, and only after the competent authority reviews it and finds it to demonstrate safety and preliminary efficacy, and it passes deliberation by the Regenerative Medicine Review Committee, may conditional approval be obtained. The role of this review committee is to bring medical, ethical, industry, patient, and review-practice perspectives to the same table and decide whether a specific product warrants trading “earlier market entry” for “subsequent verification obligations.” In other words, this is not “finish Phase II and reach market.” It is “finish Phase II and only then become eligible for a rigorous discussion of whether it can reach market conditionally.”

After obtaining conditional approval, the company receives a license valid for a maximum of five years that cannot be extended. During that period it must continue to conduct efficacy-verification trials, or submit real-world data (RWD) studies with sufficient evidentiary support, and regularly provide data to the competent authority. If the attached obligations are not fulfilled, or a major safety concern arises, the competent authority can revoke the conditional approval.

So this ticket is not a blank check. It is more like an entry qualification with an expiry date, attached obligations, and the possibility of being revoked at any time. In the first segment, completed Phase II data, risk-benefit review, and the committee’s judgment are traded for earlier access. In the second segment, efficacy-verification trials continue after market, and data is submitted regularly. If the obligations are not fulfilled, or if the competent authority assesses that a major safety concern has emerged, the approval can be revoked. This is a different matter from “relaxing review”: the latter directly lowers standards, whereas the former shifts part of the evidentiary requirement to staged fulfillment.

The second layer is the parent framework of the dual regenerative medicine laws. The Regenerative Medicine Act governs the medical-institution execution side, such as physician qualifications, institutional facilities, human trials, informed consent, and adverse-reaction reporting. The Regenerative Medicine Products Act governs the product side, folding registration review, conditional approval, manufacturing and distribution, post-market management, and drug-injury relief into a “full lifecycle management” framework close to that for conventional drugs. For companies, this means the standard of competitiveness is no longer only scientific technology, but also PIC/S GMP, GDP, batch consistency, distribution tracking, cold-chain logistics, and long-term risk-management capability.

The third layer is T-RMAT. The TFDA and the CDE announced T-RMAT in March 2026, positioning it as an accelerated guidance mechanism whose purpose is to let qualifying regenerative medicine product companies build scientific consensus with reviewers before formal submission, and to align the direction of clinical, CMC (chemistry, manufacturing, and controls), toxicology, statistics, and other data with review standards from the outset. The planned guidance model includes biweekly two-way communication with both bodies, rolling review, written review opinions, and early-consultation conclusions that have binding effect on subsequent submissions when the conditions remain consistent. When a company ultimately chooses to submit a conditional approval or BLA (biologics license application), the target review timeline can be compressed to 120 days, and the IND (investigational new drug application) targets 15 days. These figures are the target review timelines the regulator states publicly; actual submission outcomes still depend on the completeness of each case’s data.

In practice, to enter T-RMAT, the following categories of cases receive priority support: regenerative medicine products already covered by existing TFDA or CDE guidelines and consultation schemes; products planning to apply for a BLA (including conditional approval) between 2026 and 2027; first-in-human trials of exosomes or extracellular vesicles (exosome/EV); and regenerative medicine products with public health value and high clinical urgency.

Put the three layers together, and what you see is not three independent tools but a continuous design: “alignment at the scientific-consultation stage → clear conditional approval thresholds → continuation into post-market verification and safety monitoring.”

Placing Taiwan back on the map of international accelerated pathways

Placed in the global coordinate system, this pathway is not an isolated case. The U.S. FDA’s RMAT designation (Regenerative Medicine Advanced Therapy) began operating after the 21st Century Cures Act passed in 2016. According to FDA cumulative data through September 30, 2025, CBER received 388 RMAT designation requests, of which 193 were granted, 165 denied, and 14 withdrawn. These numbers make one thing clear: RMAT is not a handful of individual cases but an accelerated pathway within the U.S. regenerative medicine review system that has already accumulated considerable practical experience. The EU EMA launched PRIME (PRIority MEdicines) the same year, with the CHMP/CAT assigning a rapporteur early and providing connected services from scientific consultation to protocol assistance to accelerated assessment; in 2024 it received 58 applications and granted 15 designations.

The most instructive comparison for Taiwan is actually Japan. Japan’s Sakigake designation system, launched in 2015, places “first developed in Japan,” “early clinical data showing clear efficacy,” “addressing unmet medical need,” and “priority consultation and accelerated review” within one logic, and shortens the review timeline from 12 months to 6 months. Since 2017, Sakigake has gone further to combine with the conditional approval of regenerative medicine products, forming a Japanese version of the institutional combination “front-end accelerated guidance, back-end conditional access, then verifying efficacy and safety with post-market data.” Taiwan’s current T-RMAT plus conditional approval, though not identical in institutional detail, follows a policy logic that can be read alongside it. For therapies whose data sources span the U.S., Japan, and Europe, Taiwan’s position on this pathway will be closer to “running alongside” than the “running behind” of the past decade.

On the ground in cross-border collaboration: why many miss this pathway

From the vantage point of cross-border collaboration, what this mechanism most often runs into is not a design problem but an information gap.

Many overseas teams still understand Taiwan as “a small market whose review runs behind the U.S. and Europe, with limited incentives to enter.” But in regenerative medicine, Taiwan’s institutional updates over recent years have actually moved quickly: the dual laws take effect, conditional approval comes online, the T-RMAT guidance pilot is announced, and the Regenerative Medicine Review Committee and post-market management framework gradually take shape. These changes have not yet fully translated into shared recognition within the international industry.

Another common misjudgment is treating “Phase II plus market entry” as “lowering evidentiary requirements.” But in practice, add up the efficacy-verification obligations during the conditional approval period, post-market safety monitoring, source and distribution tracking, and drug-injury relief design, and the total compliance cost is no lighter than full approval. The real difference on this pathway is not “cheaper” but “saving time and letting patients in need reach the therapy earlier.” For therapies with real patients waiting in Taiwan, this time difference may be the difference between whether certain patients can hold on.

A third observation worth putting on the table is that this pathway is also especially suited to therapies that have already accumulated East Asian population data. The reason is not that Taiwan looks only at East Asian data, but that regenerative medicine products involve immune responses, cell dynamics, long-term safety, and process differences, so whether foreign clinical data can extrapolate to Taiwan needs to be spelled out more clearly than for ordinary drugs. If a product already has explainable clinical data in Japanese, Korean, Taiwanese, or other East Asian populations, it becomes easier during review to discuss “which data can extrapolate and which data needs reinforcement.” Many therapies currently on Japan’s Sakigake and conditional approval pathways happen to meet this condition.

In the course of cross-domain collaboration in the circular economy and semiconductors, I have seen several periods where “the system had already changed but the industry had not yet caught up.” Such periods usually produce two kinds of people: one bound by fixed impressions, continuing down a familiar but expired path; the other reading the rules over again first, adjusting their external story and internal timeline. The latter are often the ones who enter new markets fastest in the years that follow.

Not relaxing review, but shifting part of the evidentiary requirement to staged completion

If you remember only that “Phase II can reach market,” you miss the other side of conditional approval.

First, conditional approval is valid for a maximum of five years and cannot be extended upon expiry. In other words, this is not a transitional market qualification that can be extended indefinitely. If the applicant fails to complete subsequent verification and supply the data needed to support full approval within the statutory period, conditional approval cannot be maintained indefinitely.

Second, conditional approval does not mean subsequent efficacy verification is waived. By design, during the approval period the company must still continue to conduct efficacy-verification trials, or submit real-world data studies with sufficient evidentiary support, and regularly provide data to the competent authority. In practice, this can often be understood as follows: part of the confirmatory evidence normally expected to be completed before market is instead supplied continuously after market, but this does not necessarily equate to a traditional, narrowly defined Phase III.

Third, the applicant cannot simply submit clinical data and be done. Under the conditional approval system, the applicant must also submit an efficacy-verification plan, the pricing and collection method, patient relief measures, and other matters designated by the competent authority. In other words, this system requires not only scientific evidence but also financial transparency and risk-bearing arrangements for when patients actually access the therapy.

Furthermore, once a regenerative medicine product obtains conditional approval, it does not thereby escape the general drug lifecycle management requirements. Based on the competent authority’s current public statements and the context of the relevant regulations, obligations for manufacturing quality, distribution management, source and distribution tracking, post-market safety monitoring, and drug-injury relief must still be implemented in parallel. This also means that for the applicant company, conditional approval is not “secure the market qualification first and complete internal compliance later.” A considerable degree of quality and supply-chain management must be prepared before entry.

Put the above conditions together, and the real logic of this system becomes clearer. Conditional approval is not “approve first and see later.” It is the competent authority, given a specific disease, a high medical need, and preliminary support for efficacy and safety, using more intensive post-market verification, risk management, and continuous monitoring to trade for the possibility of earlier access. For companies, this is not a reduction of responsibility. It is a shift of part of that responsibility from the wait before market into regulatory obligations that must be continuously fulfilled after market.

For this reason, conditional approval, Regenerative Medicine Review Committee review, the T-RMAT guidance pilot, drug-injury relief, and full lifecycle management are not separate institutional parts. They are different links supporting the same accelerated-access logic. See only that “a product can reach market earlier” while overlooking the back-end monitoring, verification, and patient-protection design, and you misread the nature of this system.

Looking at the next decade from this pathway

Part 1, from the angle of the “data interface,” discusses how complete public data is not the same as usable data, paired with a four-language searchable tool page (30 major categories + ICD-10 codes + certification periods). Part 2, from the angle of “coverage uptake,” discusses how the tiering of catastrophic-illness certification periods already contains many of the elements needed for tiered coverage in the AI era. This piece, from the angle of the “entry pathway,” looks at how the three-layer mechanism of the dual regenerative medicine laws, conditional approval, and T-RMAT connects regenerative medicine products with “matured Phase II evidence” into Taiwan’s market and clinical-application pathway. Lay the three threads together, and you will see that after the dual regenerative medicine laws take effect, Taiwan is no longer merely discussing innovative therapies in the abstract. It has begun to concretely build an institutional framework for assessing conditional access for specific products. For the industry, the real next step is not to debate “whether Taiwan matters” in the abstract, but to judge which product types, which evidence combinations, and which timeline arrangements can actually travel this pathway.

For the global regenerative medicine industry, whether Taiwan deserves reevaluation in the coming years will depend on whether this system can accumulate actual success cases and whether the competent authority continues to provide predictable review interaction. For the policy and review sides, the completeness of the system ultimately comes back to two things: whether the safety record is stable, and whether conditional approval can actually connect smoothly to subsequent complete evidence.

For patients and families, the real meaning of this design is time. The gap in market-entry timelines for the same therapy across different countries has often been the decisive factor for fast-progressing diseases. The core value of the three-layer mechanism of the dual regenerative medicine laws, conditional approval, and T-RMAT is to release part of this time difference earlier, through “post-market verification + risk management + patient relief.” For some patients, this is not only policy progress; it is the possibility of whether they can still hold on.

For those who work in cross-border collaboration, this pathway also offers a new starting point for conversation. Over the past decade and more, Taiwan-Japan collaboration has concentrated largely in electronics, semiconductors, and circular materials. After the dual regenerative medicine laws take effect, Taiwan and Japan have one more topic to discuss together: whether Japan’s years of accumulated Sakigake and conditional-approval experience and Taiwan’s newly launched conditional approval and T-RMAT can form a workable connecting pathway in actual cases. This is one of the directions this series will keep watching.

The next piece can go further from the angle of data extrapolation, discussing bridging data under the ICH E5 framework, the definition of East Asian populations, and how the competent authority and applicants typically regard population factors and the acceptability of external data when global clinical data could directly support an application in Taiwan. This will connect the “entry pathway” discussed here further to the real technical details of an application.

Glossary

  • Regenerative Medicine Act: The law governing medical institutions’ execution of cell therapy techniques, enacted and promulgated in June 2024 and taking effect on January 1, 2026. It governs the “medical side.” For a detailed introduction, see the Part 1 glossary.
  • Regenerative Medicine Products Act: The law governing pharmaceutical companies’ research, manufacturing, and marketing of regenerative medicine products (including cell therapy drugs), enacted and promulgated in June 2024 and taking effect on January 1, 2026. It governs the “pharmaceutical-company side.” Together the two laws are called the “dual regenerative medicine laws.”
  • Conditional Approval (also called conditional approval in this article): Under Article 9 of the Regenerative Medicine Products Act, for regenerative medicine products that meet the criteria of “a life-threatening or severely disabling disease,” “completed Phase II human trials,” and “data submitted by the applicant that upon review demonstrates safety and preliminary efficacy and passes deliberation by the Regenerative Medicine Review Committee,” conditional approval may be granted for no more than five years and may not be extended.
  • T-RMAT (Taiwan Regenerative Medicine Advanced Therapy Pilot): The regenerative medicine product guidance pilot announced and advanced by the TFDA and the CDE in March 2026, focused on pre-submission regulatory and scientific consultation, review preparation, and increased communication density. The publicly stated target review timelines are 120 days for a BLA (including conditional approval) and 15 days for an IND; actual case outcomes still depend on data completeness. Its naming logic aligns with the U.S. FDA’s RMAT designation.
  • Regenerative Medicine Review Committee: The review body established under the Regenerative Medicine Products Act, responsible for deliberating major matters such as conditional approval and efficacy-verification plans.
  • FDA RMAT (Regenerative Medicine Advanced Therapy Designation): The U.S. FDA’s regenerative medicine accelerated pathway, in operation since the 21st Century Cures Act passed in 2016. For cell therapy, tissue engineering, and gene therapy products that treat serious or life-threatening diseases and whose preliminary clinical evidence shows the potential to address unmet medical need, it provides support such as accelerated approval, rolling review, and close interaction.
  • EMA PRIME (PRIority MEdicines): The priority medicines program operated by the European Medicines Agency since March 2016, providing support such as early assignment of a CHMP/CAT rapporteur, iterative scientific consultation, and accelerated assessment.
  • PMDA Sakigake: The “Sakigake” (さきがけ) designation system operated by Japan’s Ministry of Health, Labour and Welfare since 2015, a pioneering review system worth comparing against. It provides accelerated review for medical products first developed in Japan whose early data show clear efficacy, and since 2017 has gone further to combine with the conditional approval of regenerative medicine products, forming a Japanese version of the two-layer architecture “accelerated design + earlier access.”
  • ICH E5: The International Council for Harmonisation’s guideline on ethnic factors and the acceptability of foreign clinical data, the foundational framework for bridging-data arguments. The next piece will unpack this in depth.
  • PIC/S GMP: Good Manufacturing Practice for pharmaceuticals.
  • GDP (Good Distribution Practice): Good Distribution Practice for pharmaceuticals.
  • RWD (Real-World Data): Health-related data collected in routine medical settings, such as electronic medical records, health insurance data, registry databases, and patient-reported outcomes, which can be used to support efficacy verification during the conditional approval period.

Note: This article is a compilation of public information and institutional observation. It does not constitute medical, legal, investment, clinical trial design, or pharmaceutical application advice. Whether an individual product qualifies for conditional approval, whether it is suitable for entering T-RMAT, and whether overseas clinical data can be accepted should still be determined by the latest announcements of the Ministry of Health and Welfare Food and Drug Administration and the Center for Drug Evaluation, and by the Regenerative Medicine Act, the Regenerative Medicine Products Act, and related subsidiary regulations.

Sources: